Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 254

Similar articles for PubMed (Select 23557519)

1.

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

Huber K, Connolly SJ, Kher A, Christory F, Dan GA, Hatala R, Kiss RG, Meier B, Merkely B, Pieske B, Potpara T, Stępińska J, Klun NV, Vinereanu D, Widimský P.

Int J Clin Pract. 2013 Jun;67(6):516-26. doi: 10.1111/ijcp.12147. Epub 2013 Apr 5. Review.

2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
4.

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Skjøth F, Larsen TB, Rasmussen LH, Lip GY.

Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.

PMID:
24577485
5.

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.

Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.

PMID:
22318514
6.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

7.

Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.

Deitelzweig S.

Cardiovasc Ther. 2014 Apr;32(2):74-81. doi: 10.1111/1755-5922.12048. Review.

PMID:
24119252
8.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

9.

Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

Mangiafico RA, Mangiafico M.

Curr Med Chem. 2012;19(27):4688-98. Review.

PMID:
22830344
10.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

11.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Scaglione F.

Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. Review.

PMID:
23292752
12.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
13.

Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.

Akwaa F, Spyropoulos AC.

Hosp Pract (1995). 2013 Feb;41(1):8-18. doi: 10.3810/hp.2013.02.1008. Review.

PMID:
23466963
14.

New oral anticoagulants in non-valvular atrial fibrillation.

Francia P, Adduci C, Santini D, Musumeci B, Tocci G.

High Blood Press Cardiovasc Prev. 2013 Jun;20(2):53-60. doi: 10.1007/s40292-013-0011-6. Epub 2013 May 8. Review.

PMID:
23653173
15.

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.

Ellis CR, Kaiser DW.

Vasc Health Risk Manag. 2013;9:341-52. doi: 10.2147/VHRM.S28271. Epub 2013 Jul 9. Review.

16.

Dabigatran etexilate: future directions in anticoagulant treatment.

Schulman S, Reilly PA.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13. Review.

PMID:
19679590
17.

Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.

Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.

Thromb Haemost. 2013 Feb;109(2):328-36. doi: 10.1160/TH12-08-0539. Epub 2012 Nov 22.

PMID:
23179181
18.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
19.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
20.

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S.

Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005.

PMID:
19376304
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk